Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume

Shares of Pharming Group (NASDAQ:PHAR - Get Free Report) saw an uptick in trading volume on Thursday . 2,510 shares changed hands during mid-day trading, a decline of 2% from the previous session's volume of 2,557 shares.The stock last traded at $9.37 and had previously closed at $10.45.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a "buy" rating and set a $37.00 price target on shares of Pharming Group in a report on Thursday, March 14th.

Pharming Group Stock Down 4.3 %

The company has a fifty day simple moving average of $10.75 and a 200-day simple moving average of $11.37. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.62. The firm has a market cap of $671.09 million, a P/E ratio of -68.78 and a beta of 0.20.

Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.08). Pharming Group had a negative net margin of 4.13% and a negative return on equity of 4.53%. The business had revenue of $81.20 million during the quarter, compared to analysts' expectations of $71.83 million. On average, equities analysts anticipate that Pharming Group will post -0.02 earnings per share for the current year.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. Orion Portfolio Solutions LLC bought a new position in Pharming Group (NASDAQ:PHAR - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 11,715 shares of the company's stock, valued at approximately $134,000. Hedge funds and other institutional investors own 0.03% of the company's stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.